Prognostic value of F-18-fluorodeoxyglucose PET/computed tomography metabolic parameters measured in the primary tumor and suspicious lymph nodes before neoadjuvant therapy in patients with esophageal carcinoma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTUSTUMI, Francisco
dc.contributor.authorDUARTE, Paulo Schiavom
dc.contributor.authorALBENDA, David Gutierrez
dc.contributor.authorTAKEDA, Flavio Roberto
dc.contributor.authorSALLUM, Rubens Antonio Aissar
dc.contributor.authorRIBEIRO JUNIOR, Ulysses
dc.contributor.authorBUCHPIGUEL, Carlos Alberto
dc.contributor.authorCECCONELLO, Ivan
dc.date.accessioned2021-06-17T13:52:34Z
dc.date.available2021-06-17T13:52:34Z
dc.date.issued2021
dc.description.abstractBackground F-18-fluorodeoxyglucose PET/computed tomography (F-18-FDG PET/CT) metabolic parameters are prognostic indicators in several neoplasms. This study aimed to evaluate the prognostic value of the maximum and average standardized uptake value (SUVmax and SUVavg), metabolic tumor value (MTV), and total lesion glycolysis (TLG) measured in the primary tumor and suspicious lymph nodes preneoadjuvant therapy in patients submitted to surgical resection for esophageal cancer. Methods A cohort of 113 patients with esophageal cancer who performed F-18-FDG PET/CT preneoadjuvant therapy was assessed. The association of the SUV, MTV, and TLG measured in the primary tumor and in the suspicious lymph nodes with the overall survival was assessed. It was also analyzed other potentially confounding variables such as age, sex, clinical stage, and histologic subtype. The analyses were performed using Kaplan-Meier curve, log-rank test, and Cox regression. Results The univariate analyses showed that the MTV and TLG in the primary tumor, the SUV in the suspicious lymph nodes, the age, the histologic subtype, and the clinical stage were associated with survival after surgery (P <= 0.05). In the Cox regression multivariate analyses, all variables identified in the univariate analyses but the clinical stage were associated with survival after surgery (P <= 0.05). Conclusion In esophageal cancer patients, some of the F-18-FDG PET/CT metabolic parameters measured in the primary tumor and in the suspicious lymph nodes before the neoadjuvant therapy are independent indicators of overall survival and appear to be more important than the clinical stage in the prognostic definition of this group of patients.eng
dc.description.indexMEDLINEeng
dc.identifier.citationNUCLEAR MEDICINE COMMUNICATIONS, v.42, n.4, p.437-443, 2021
dc.identifier.doi10.1097/MNM.0000000000001347
dc.identifier.eissn1473-5628
dc.identifier.issn0143-3636
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/40679
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofNuclear Medicine Communications
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subjectesophageal neoplasmseng
dc.subjectneoadjuvant therapyeng
dc.subjectnuclear medicineeng
dc.subjectPETeng
dc.subject.wosRadiology, Nuclear Medicine & Medical Imagingeng
dc.titlePrognostic value of F-18-fluorodeoxyglucose PET/computed tomography metabolic parameters measured in the primary tumor and suspicious lymph nodes before neoadjuvant therapy in patients with esophageal carcinomaeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus8
hcfmusp.contributor.author-fmusphcFRANCISCO TUSTUMI
hcfmusp.contributor.author-fmusphcPAULO SCHIAVOM DUARTE
hcfmusp.contributor.author-fmusphcDAVID ALBERTO GUTIERREZ ALBENDA
hcfmusp.contributor.author-fmusphcFLAVIO ROBERTO TAKEDA
hcfmusp.contributor.author-fmusphcRUBENS ANTONIO AISSAR SALLUM
hcfmusp.contributor.author-fmusphcULYSSES RIBEIRO JUNIOR
hcfmusp.contributor.author-fmusphcCARLOS ALBERTO BUCHPIGUEL
hcfmusp.contributor.author-fmusphcIVAN CECCONELLO
hcfmusp.description.beginpage437
hcfmusp.description.endpage443
hcfmusp.description.issue4
hcfmusp.description.volume42
hcfmusp.origemWOS
hcfmusp.origem.pubmed33306638
hcfmusp.origem.scopus2-s2.0-85102910414
hcfmusp.origem.wosWOS:000639304900013
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceBROWN RS, 1995, J NUCL MED, V36, P1854eng
hcfmusp.relation.referenceButof R, 2015, J NUCL MED, V56, P1150, DOI 10.2967/jnumed.115.155309eng
hcfmusp.relation.referenceCacicedo J, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160217eng
hcfmusp.relation.referenceCastelli J, 2019, EUR J NUCL MED MOL I, V46, P638, DOI 10.1007/s00259-018-4134-9eng
hcfmusp.relation.referenceChang S, 2016, CANCER BIOTHER RADIO, V31, P1, DOI 10.1089/cbr.2015.1932eng
hcfmusp.relation.referenceChen PJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07044-4eng
hcfmusp.relation.referenceChung HH, 2012, ANN SURG ONCOL, V19, P1966, DOI 10.1245/s10434-011-2153-xeng
hcfmusp.relation.referenceDamhuis Ronald A M, 2005, World J Surg Oncol, V3, P71, DOI 10.1186/1477-7819-3-71eng
hcfmusp.relation.referenceDibble EH, 2012, J NUCL MED, V53, P709, DOI 10.2967/jnumed.111.099531eng
hcfmusp.relation.referenceElimova E, 2015, EUR J CANCER, V51, P2545, DOI 10.1016/j.ejca.2015.07.044eng
hcfmusp.relation.referenceHatt M, 2011, EUR J NUCL MED MOL I, V38, P1595, DOI 10.1007/s00259-011-1834-9eng
hcfmusp.relation.referenceHatt M, 2011, EUR J NUCL MED MOL I, V38, P1191, DOI 10.1007/s00259-011-1755-7eng
hcfmusp.relation.referenceHofheinz F, 2019, EUR J NUCL MED MOL I, V46, P1485, DOI 10.1007/s00259-019-04307-6eng
hcfmusp.relation.referenceHong JH, 2016, J KOREAN MED SCI, V31, P39, DOI 10.3346/jkms.2016.31.1.39eng
hcfmusp.relation.referenceHyun SH, 2010, ANN SURG ONCOL, V17, P115, DOI 10.1245/s10434-009-0719-7eng
hcfmusp.relation.referenceJayachandran P, 2012, INT J RADIAT ONCOL, V84, P471, DOI 10.1016/j.ijrobp.2011.12.029eng
hcfmusp.relation.referenceJin F, 2018, CLIN LUNG CANCER, V19, pE101, DOI 10.1016/j.cllc.2017.06.006eng
hcfmusp.relation.referenceKelsen DP, 1998, NEW ENGL J MED, V339, P1979, DOI 10.1056/NEJM199812313392704eng
hcfmusp.relation.referenceLAUSEN B, 1992, BIOMETRICS, V48, P73, DOI 10.2307/2532740eng
hcfmusp.relation.referenceLee HY, 2010, ANN SURG ONCOL, V17, P2787, DOI 10.1245/s10434-010-1107-zeng
hcfmusp.relation.referenceLemarignier C, 2014, EUR J NUCL MED MOL I, V41, P2008, DOI 10.1007/s00259-014-2839-yeng
hcfmusp.relation.referenceLi YM, 2015, INT J CLIN EXP MED, V8, P10947eng
hcfmusp.relation.referenceLiao SR, 2012, EUR J NUCL MED MOL I, V39, P27, DOI 10.1007/s00259-011-1934-6eng
hcfmusp.relation.referenceLim R, 2012, J NUCL MED, V53, P1506, DOI 10.2967/jnumed.111.101402eng
hcfmusp.relation.referenceLin CH, 2020, CANCERS, V12, DOI 10.3390/cancers12030607eng
hcfmusp.relation.referenceLu CH, 2018, ASIAN J SURG, V41, P333, DOI 10.1016/j.asjsur.2017.02.008eng
hcfmusp.relation.referenceMac Manus M, 2008, INT J RADIAT ONCOL, V72, P1298, DOI 10.1016/j.ijrobp.2008.08.022eng
hcfmusp.relation.referenceMeacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624eng
hcfmusp.relation.referenceMeyers BF, 2007, J THORAC CARDIOV SUR, V133, P738, DOI 10.1016/j.jtcvs.2006.09.079eng
hcfmusp.relation.referenceMoon SH, 2013, HEAD NECK-J SCI SPEC, V35, P15, DOI 10.1002/hed.22904eng
hcfmusp.relation.referenceMota FC, 2018, INT J SURG, V54, P176, DOI 10.1016/j.ijsu.2018.04.053eng
hcfmusp.relation.referenceOdawara S, 2018, EUR J RADIOL, V101, P65, DOI 10.1016/j.ejrad.2018.02.009eng
hcfmusp.relation.referenceReynolds JV, 2007, ANN SURG, V245, P707, DOI 10.1097/01.sla.0000254367.15810.38eng
hcfmusp.relation.referenceRice TW, 2017, ANN CARDIOTHORAC SUR, V6, P119, DOI 10.21037/acs.2017.03.14eng
hcfmusp.relation.referenceSchwartz DL, 2015, INT J RADIAT ONCOL, V91, P721, DOI 10.1016/j.ijrobp.2014.12.023eng
hcfmusp.relation.referenceSon SH, 2018, CLIN NUCL MED, V43, pE296, DOI 10.1097/RLU.0000000000002188eng
hcfmusp.relation.referenceSoydal C, 2014, MOL IMAGING RADIONUC, V23, P12, DOI 10.4274/Mirt.07379eng
hcfmusp.relation.referencevan Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088eng
hcfmusp.relation.referenceVlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108eng
hcfmusp.relation.referenceYap WK, 2017, DIS ESOPHAGUS, V30, DOI 10.1093/dote/dox021eng
hcfmusp.relation.referenceYap WK, 2018, EUR J NUCL MED MOL I, V45, P689, DOI 10.1007/s00259-017-3901-3eng
hcfmusp.relation.referenceZhu WY, 2018, ONCOTARGETS THER, V11, P4345, DOI 10.2147/OTT.S160456eng
hcfmusp.scopus.lastupdate2024-05-11
relation.isAuthorOfPublicationb198d885-85d1-4da2-bf9f-de22e2308c6c
relation.isAuthorOfPublicationf5dbbb8c-c66c-4c03-88a2-58cb059b893a
relation.isAuthorOfPublicationc0eb0303-d05a-4faf-a5ea-49ca7cff0032
relation.isAuthorOfPublicationa283b288-880f-4ed0-8e83-c2c3eff2f05a
relation.isAuthorOfPublicationd1507f94-6ef4-4ca9-8784-b1499b5dfae6
relation.isAuthorOfPublicationa4bfdcf9-89f7-472f-9936-aa817156faad
relation.isAuthorOfPublication6fcbbc21-1ba0-4023-a2cd-0e709b22f5c3
relation.isAuthorOfPublicatione0a211ed-1f62-4700-bf7b-a7cd39218361
relation.isAuthorOfPublication.latestForDiscoveryb198d885-85d1-4da2-bf9f-de22e2308c6c
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Carregar mais